Market Updates: Key Upgrades and Downgrades
Wall Street has been buzzing about various research requests that are influencing market movements. Here’s a summary of today’s notable findings that investors should take note of.
Top 5 Upgrades:
JP Morgan is optimistic about NetEase (NTES), moving its rating from Neutral to Overweight and raising the price target from $138 to $190. The firm is excited about the upcoming game releases scheduled for 2026.
Morgan Stanley has revised its rating on Sienna (CIEN), shifting from Underweight to Equal Weight, with a price target increase from $100 to $140. They believe concerns about margins were overstated, especially as demand trends are improving.
HSBC upgraded Synchrony (SYF), adjusting its rating to “Buy” from Hold and increasing the price target from $73 to $81. The rationale includes Synchrony’s solid credit performance and promising growth prospects.
Macquarie has upgraded Baidu (BIDU), changing the price target range from $91 to $176, with a rating change from Neutral to Outperform. They noted Baidu’s diversification in revenue streams, particularly in cloud services and AI technologies.
Baird has changed its outlook on Littelfuse (LFUS), raising the price target from $290 to $310, now rating it as Outperform. The firm highlighted that Littelfuse’s engagement in artificial intelligence is already yielding positive early results.
Top 5 Downgrades:
Jefferies downgraded Align Technology (ALGN), lowering the price target from $215 to $140 and shifting the rating from Buy to Hold. Recent dental surveys in the U.S. reflected mixed and negative sentiment about clear aligners, contributing to Align’s stock decline.
RBC Capital has downgraded Mosaic (MOS) from Outperform to Sector Perform and reduced the price target from $40 to $30. They expressed disappointment over another unexpected phosphate production cut, which they believe will hurt Mosaic’s stock considerably.
JP Morgan has downgraded Doximity (DOCS) from Neutral to Underweight, keeping the price target steady at $62. They view the stock’s premium valuation as excessive and noted that uncertain trends in pharmaceutical digital advertising are obscuring Doximity’s growth potential.
JP Morgan also downgraded Pliant Therapeutics (PLRX) from Neutral to Underweight without a price target. The firm commented on the stalled investment discussions following the discontinuation of its bexotegrast program for idiopathic pulmonary fibrosis, suggesting the company is now in a waiting phase.
Morgan Stanley adjusted its outlook on Keysight Technology (KEYS), changing the rating from Overweight to Equal Weight while keeping the price target unchanged at $180. They noted that the stock has already reached its target price, lacking additional catalysts for a re-evaluation.
